Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep

Merck has extended Keytruda's lifecycle by launching subcutaneous Qlex, securing its exclusivity through 2039, and other extensions supporting market confidence.

Recent regulatory approvals, promising pipeline updates, and two major acquisitions (Terns, Cidara) have broadened MRK’s oncology and virology portfolios.

Analyst long-term EPS estimates have improved, but the stock’s 17% rally since the latest quarterly results and 2030–32 P/E of ~13.5 suggest the current valuation is fully justified.

I maintain a HOLD rating, as risk-reward is less compelling post-rally, though MRK’s innovation and management execution remain strong.